CAMBIUM BIO LIMITED
ASX:CMBPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 91.8% of what they think they own, once every option and right converts.
Runway under 2 quarters; share count grew 147% in 24 months; 6 cash raises in 24 months
CAMBIUM BIO LIMITED's ordinary share count grew 146.7% between June 2024 and July 2026, to 29M shares, with the latest share count adjusted for a consolidation. The company raised capital six times in the past 24 months for total disclosed proceeds of A$18.5M, most recently a A$1.0M placement in July 2026. Options and rights on issue could convert into 3M new shares, equal to 8.9% of the current share count; no filing on record states an expiry date for these securities, and 0% are in the money at the current share price. At the June 2026 quarter the company reported A$1.5M in available cash, about 1.8 quarters of funding at its recent spending rate. No proposed securities issues are pending.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 1 Sept 2026 | 3G · unquoted | CMB : ORDINARY FULLY PAID | 29.4M | Appendix 3G |
| 23 July 2026 | 2A · quoted issue | CMB : ORDINARY FULLY PAID | 29.4M | Appendix 2A |
| 16 Mar 2026 | 2A · quoted issue | CMB : ORDINARY FULLY PAID | 27.3M | Appendix 2A |
| 16 Oct 2025 | 2A · quoted issue | CMB : ORDINARY FULLY PAID | 23.0M | Appendix 2A |
| 16 Oct 2025 | 3G · unquoted | CMB : ORDINARY FULLY PAID | 22.9M | Appendix 3G |
Capital raises
6 cash raises in the last 24 months · 4 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 2.6M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| CMBAQ | Options | Price-triggered | — | — | 2.6M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 17 Mar 2026 | YU-HUNG SEBASTIAN TSENG | Other placement | 4.4M | — | — | — | 3Y notice |
| 16 Oct 2025 | EDMUND KEMP WALLER | Other | 60k | 120k | — | — | 3Y notice |
| 16 Oct 2025 | TERENCE ALLEN WALTS | Other | 55k | 120k | — | — | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.